{"filings":[{"id":1361402,"accession_number":"0001193125-26-290649","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-06-30T20:30:29+00:00","items":["5.07"],"status":"ready","headline":"Septerna stockholders elect Shalini Sharp and Jake Simson as Class II directors; ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shalini Sharp elected with 33,732,317 votes for, 5,808,264 withheld, 1,969,475 broker non-votes.","Jake Simson elected with 33,716,857 votes for, 5,823,724 withheld, 1,969,475 broker non-votes.","Ratification of Ernst & Young as auditor for FY 2026 passed with 41,207,237 for, 4,008 against, 298,811 abstain.","Annual meeting held June 26, 2026; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12892,"accession_number":"0001193125-26-216723","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-05-11T20:05:14+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.","Cash $522.1M as of March 31, 2026; expected runway into 2029.","SEP-631 Phase 1 positive: well tolerated, supports once-daily dosing; Phase 2b in CSU planned H2 2026.","SEP-479 Phase 1 trial for hypoparathyroidism initiated; data expected late 2026/early 2027.","CMO Jae Kim departing; successor search initiated; will serve advisory role during transition."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":26523000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97068,"accession_number":"0001193125-26-152045","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna dosed first participants in Phase 1 trial of SEP-479 oral PTH1R agonist for hypoparathyroidism","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 SAD/MAD trial evaluating safety, tolerability, PK/PD in up to 150 healthy volunteers.","SEP-479 is a potent oral small molecule PTH1R agonist for hypoparathyroidism, a lifelong condition.","Data from the trial expected in late 2026 or early 2027.","CEO highlights potential as once-daily oral therapy, differentiating from daily injections or calcium supplements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111545,"accession_number":"0001193125-26-098489","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna posts Q4 net loss $10.7M, highlights positive Phase 1 data for SEP-631","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1 data: SEP-631 well-tolerated, once-daily oral dosing, complete wheal inhibition at 10 mg; Phase 2b in CSU planned H2 2026.","SEP-479 PTH1R agonist on track for Phase 1 initiation in first half of 2026.","Cash $548.7M at Dec 31, 2025; runway at least into 2029 (includes $195M upfront from Novo Nordisk).","Q4 2025 revenue $24.1M (collaboration revenue); net loss $10.7M vs $20.7M loss in Q4 2024.","Appointed Mark A. Wilson as chief legal officer in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111544,"accession_number":"0001193125-26-084142","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Septerna reports positive Phase 1 data for oral MRGPRX2 NAM SEP-631, plans Phase 2 in chronic spontaneous urticaria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SEP-631 well-tolerated; adverse event profile comparable to placebo across all doses studied","Complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily","Pharmacokinetic profile supports once-daily dosing with approximately 24-hour half-life","Company plans Phase 2b trial in chronic spontaneous urticaria in the second half of 2026"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111543,"accession_number":"0001193125-26-009864","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna at J.P. Morgan Healthcare Conference; no material news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated January 2026 furnished to SEC; no financial results or clinical updates included.","Company conducting standard investor meetings at the conference; no strategic transactions announced.","Presentation highlights Septerna's GPCR drug discovery platform but does not disclose new data or partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111542,"accession_number":"0001193125-26-007772","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna appoints Mark A. Wilson as Chief Legal Officer, effective January 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark A. Wilson joins from Nektar Therapeutics, where he was SVP and Chief Legal Officer.","He has over 25 years of experience in IP, corporate legal, and strategic collaborations.","Wilson will oversee legal, IP strategy, and governance for Septerna's GPCR drug discovery pipeline.","He previously led global collaborations and patent strategy at Nektar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128160,"accession_number":"0001193125-25-273373","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.","Cash and equivalents $561.6M, including $195M upfront from Novo Nordisk and $12.5M from Vertex; runway into 2029.","Selected SEP-479 as oral PTH1R agonist development candidate for hypoparathyroidism; Phase 1 expected H1 2026.","SEP-631 Phase 1 ongoing for mast cell diseases; initial data expected H1 2026.","Appointed Keith Gottesdiener, M.D., to Board as chair of R&D Committee."],"consensus_eps_estimate":0.8099,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":21833000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144965,"accession_number":"0001193125-25-223292","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Septerna appoints Keith Gottesdiener, M.D. to board as Class I director and R&D Committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective Sept 25; board expanded to eight; Gottesdiener serves three-year term until 2028.","Also appointed to Compensation Committee and as chair of newly constituted R&D Committee effective Sept 26.","Gottesdiener is independent under Nasdaq/SEC rules; no material transactions or family relationships with officers.","Compensation per standard non-employee director policy plus $12,000 annual retainer for R&D Committee chair.","Former CEO of Prime Medicine and Rhythm Pharmaceuticals; 16 years at Merck with over 20 drug approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144964,"accession_number":"0001193125-25-194472","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna updates corporate presentation for investor meetings; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation dated September 2025 for use with investors and analysts.","Presentation focuses on Septerna's GPCR drug discovery platform.","No financial results, clinical data, or guidance changes were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144963,"accession_number":"0001193125-25-184706","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna doses first participants in Phase 1 trial of SEP-631 for mast cell-driven diseases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SEP-631 is an oral small molecule MRGPRX2 negative allosteric modulator (NAM) targeting chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.","Phase 1 SAD/MAD trial will evaluate safety, tolerability, PK and PD in up to ~150 healthy volunteers; SAD dosing is underway.","PD assessed via icatibant skin challenge in the MAD portion; no financial or guidance updates provided.","Septerna highlights unmet need in CSU where many patients do not respond to antihistamines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144962,"accession_number":"0000950170-25-106540","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna Q2 net loss $24.8M; cash $379.2M; Novo Nordisk upfront $195M extends runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.8M for Q2 2025, up from $16.4M in Q2 2024; R&D expenses $22.2M, G&A $6.9M.","Cash, cash equivalents and marketable securities $379.2M at June 30, 2025; plus $195M upfront from Novo Nordisk received in July, extending cash runway at least into 2029.","PTH1R agonist program: development candidate selection expected in Q3 2025, Phase 1 start in H1 2026.","SEP-631 Phase 1 trial initiating in Q3 2025 for mast cell diseases.","COO Liz Bhatt promoted to President effective August 1, 2025."],"consensus_eps_estimate":0.8772,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":338000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144961,"accession_number":"0001193125-25-172595","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Septerna appoints COO Liz Bhatt as President effective Aug 1, 2025; CEO Finer remains","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Liz Bhatt appointed President, effective Aug 1, 2025, while continuing as Chief Operating Officer.","Jeffrey Finer, M.D., Ph.D., remains CEO and principal executive officer after the change.","Bhatt has served as COO since June 2022; no new compensation or arrangements disclosed.","No family relationships or material transactions involving Bhatt per Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144960,"accession_number":"0001193125-25-154955","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Septerna and Novo Nordisk collaboration becomes effective after HSR clearance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration and License Agreement with Novo Nordisk became effective July 1, 2025.","Early termination of HSR waiting period triggered effectiveness of May 13, 2025 deal.","Summary of terms previously filed in May 14, 2025 8-K; full agreement to be filed in Q2 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163340,"accession_number":"0001193125-25-142747","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Septerna stockholders elect two Class I directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Abraham Bassan and Alan Ezekowitz elected as Class I directors with ~29.3M and ~29.2M votes for, respectively.","Ratification of Ernst & Young as auditor for FY2025 passed with 34.2M votes in favor.","34.3M of 44.5M outstanding shares voted, establishing quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163339,"accession_number":"0000950170-25-072612","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna reports Q1 net loss $21.5M, $398.2M cash; Novo Nordisk deal up to $2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration with Novo Nordisk for oral small molecules in metabolic diseases: >$200M upfront and near-term, up to $2.2B total milestones plus royalties.","Cash, cash equivalents, and marketable securities were $398.2M as of March 31, 2025; prior runway extended beyond early 2028.","Q1 net loss $21.5M vs $14.2M YoY; R&D expense $19.3M, G&A $6.9M.","On track to select next-gen oral PTH1R agonist candidate by end of 2025; SEP-631 Phase 1 initiation expected Q3 2025.","Novo Nordisk to cover all R&D costs for partnered programs; Septerna can opt-in to profit-share on one program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":219000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163338,"accession_number":"0001193125-25-119386","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Septerna & Novo Nordisk partner on oral small molecule obesity drugs; upfront $195M, potential $2.2B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Collaboration covers up to 5 GPCR targets (GLP-1, GIP, glucagon) for oral small molecule therapies for obesity/T2D.","Upfront payment of $195M; total potential milestones exceed $2.2B; mid-to-high single-digit royalties on global sales.","Novo covers 100% of R&D costs; Septerna retains its Native Complex Platform and all other programs.","Septerna has option to convert to profit-share on one program in lieu of milestones/royalties.","Phase 1 trial of SEP-631 (MRGPRX2 antagonist for chronic urticaria) expected to start Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181274,"accession_number":"0001193125-25-064729","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna reports FY2024 net loss of $71.8M, discontinues SEP-786 Phase 1 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Discontinued SEP-786 Phase 1 trial after two Grade 3 elevated unconjugated bilirubin events, reversible without liver injury.","Plans to select a next-generation oral PTH1R agonist candidate by end of 2025 to advance toward clinic.","SEP-631 MRGPRX2 NAM program on track to initiate Phase 1 trial in 2025 for mast cell diseases.","Cash, equivalents, and marketable securities $420.8M at Dec 31, 2024; runway into early 2028.","Appointed Gil Labrucherie as CFO in January 2025; net loss $20.7M in Q4 2024, $71.8M for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181273,"accession_number":"0001193125-25-044229","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna presents at TD Cowen conference; no material new disclosures in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Participated in TD Cowen 45th Annual Health Care Conference on March 3, 2025.","Corporate presentation furnished as Exhibit 99.1; no financial results or guidance included.","No updates to pipeline, leadership, or capital structure reported in the filing.","Filing is a routine Regulation FD disclosure with no substantive news."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181272,"accession_number":"0001193125-25-028247","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna discontinues SEP-786 Phase 1 trial after bilirubin events; plans next-gen PTH1R agonist","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued SEP-786 Phase 1 trial due to two Grade 3 unconjugated bilirubin events without ALT/AST elevation; no SAEs or liver injury.","Multiple next-generation oral PTH1R agonists in portfolio; candidate selection and clinic entry expected later in 2025.","Cash, cash equivalents, and marketable securities $137.5M as of Sep 30, 2024; plus $302.6M from Oct IPO; runway into H2 2027.","Also advancing SEP-631 (MRGPRX2 negative allosteric modulator) for mast cell diseases; clinical initiation planned later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181271,"accession_number":"0001193125-25-004909","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Septerna presents at J.P. Morgan Healthcare Conference; no financial or pipeline updates in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company is conducting meetings at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025.","Corporate presentation furnished as Exhibit 99.1, but not filed or incorporated by reference.","No earnings, trial results, or other material disclosures included in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181270,"accession_number":"0001193125-25-001834","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Septerna appoints Gil Labrucherie as CFO effective Jan 6, 2025; interim CFO Ran Xiao resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gil Labrucherie appointed CFO, principal financial and accounting officer, effective Jan 6, 2025.","Labrucherie brings 25+ years biotech experience, most recently CFO of Acelyrin and Nektar Therapeutics.","Compensation includes $485k base salary, 40% target bonus, and stock option for 222,000 shares.","Interim CFO Ran Xiao resigns from CFO role but remains VP of Finance and Business Operations.","Labrucherie has raised over $1.5B in equity and generated $1B+ in strategic partnering value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198099,"accession_number":"0001193125-24-262539","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.","Cash, equivalents, and marketable securities $137.5M as of Sep 30, 2024; plus $302.6M net IPO proceeds in Oct 2024 extend runway into H2 2027.","Phase 1 trial of SEP-786 (oral PTH1R agonist for hypoparathyroidism) ongoing; data expected mid-2025.","SEP-631 (MRGPRX2 NAM for CSU) in IND-enabling studies; TSHR NAM program for Graves' disease progressing.","Jae Kim, M.D. appointed CMO in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-21.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":863000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198098,"accession_number":"0001193125-24-245578","cik":1984086,"company_name":"Septerna, Inc.","ticker":"SEPN","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Septerna amends charter and bylaws post-IPO, authorizes 500M common and 10M preferred shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.","Eliminated references to previously existing series of preferred stock.","Bylaws remove stockholder ability to act by written consent and to call special meetings.","Bylaws establish advance notice procedures for stockholder proposals and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1359478056.9855654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}